COMPANY PROFILE

LinqMed

Explore full profile

Innovative cancer therapy through advanced radioactive drugs, enhancing health and well-being

Tokyo, JapanFounded 2022Biotech & Life Sciences

Valuation $50–100M Last recorded · 2025

Total funding $10–50M Disclosed equity funding

Unlock exact values

About LinqMed

Link Med Co., Ltd. specializes in the development and manufacture of advanced radioactive drugs aimed at innovative cancer therapy. Operating in the healthcare and pharmaceutical market, Link Med serves hospitals, clinics, and medical research institutions. The company leverages cutting-edge science to create effective treatments that improve patient outcomes and overall well-being. Link Med's business model revolves around the production and sale of these specialized drugs, generating revenue through direct sales to healthcare providers and partnerships with medical institutions. The company is committed to advancing medical science and providing state-of-the-art solutions for cancer treatment.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Tokyo, Japan
Open positions: None listed
Dealroom signal: 49.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	May 2025	$2.3M	$58M	Nissay Capital	↗
SERIES B✓Equity / VC	Apr 2025	—	—	Mitsubishi UFJ Capital	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

LinqMed website traffic

Latest recorded traffic for LinqMed is 780 monthly website visits, down 74.8% over the last three months.

Latest monthly visits780 3-month web change-74.8%

Monthly website visitsDec 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
KTKailera TherapeuticsA clinical-stage biopharma company advancing a diverse therapeutic pipeline aimed at delivering innovative treatments for obesity and related conditions	Waltham, United States	Operational	182	$1B	$1.1B
MEMetseraMetsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases	New York City, United States	Acquired
MIMetrodora InstituteA medical and research center dedicated to advancing care and accelerating cures for people living with neuroimmune axis disorders	Salt Lake City, United States	Operational
VBVero BiotechAn emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions	Atlanta, United States	Operational
SYSydnexisBiotech & Life Sciences	Del Mar, United States	Operational
CHCabinet HealthA sustainable healthcare company, starting with over-the-counter medicine	New York City, United States	Operational
GAGalenicumProduction and distribution of pharmaceutical goods in various formats	Esplugues de Llobregat, Spain	Operational
XBXeno BiosciencesXeno Biosciences, Inc operates as a biopharmaceutical company	Somerville, United States	Operational